Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days
NºPublicación: WO2017026843A1 16/02/2017
THE CATHOLIC UNIV OF KOREA INDUSTRY-ACADEMIC COOP FOUND [KR]
RES BUSINESS FOUND SUNGKYUNKWAN UNIV [KR]
The present invention relates to a method for providing information on chronic myeloid leukemia by using Cordon-bleu protein-like 1 (Cobll1). More particularly, the present invention can: simultaneously provide a variety of information such as a diagnosis of the transition from chronic myeloid leukemia to the blastic phase, a prognosis prediction after the transition from chronic myeloid leukemia to the blastic phase, and resistance to various therapeutic agents, for chronic myeloid leukemia, including tyrosine kinase inhibitors; and be used in the diagnosis of patients who have not received a prediction and a diagnosis by conventional BCR-ABL1 gene measurement, and thus the present invention is expected to be usable in various prognosis predictions and diagnoses, of the chronic myeloid leukemia, such as the progression, recurrence, and drug resistance thereof. In addition, an oligonucleotide, of the present invention, specifically binding to a Cobll1 mRNA can be used in effectively inhibiting the proliferation of cells and the resistance to drugs by inhibiting the expression of a Cobll1 protein, and thus the oligonucleotide is expected to be able to treat chronic myeloid leukemia and effectively inhibit the transition from chronic myeloid leukemia to the blastic phase.
NºPublicación: WO2017027571A1 16/02/2017
DANA-FARBER CANCER INST INC [US]
The present disclosure provides combination therapy comprising a BET inhibitor and a protein phosphatase 2A (PP2A) activator, a B-cell lymphoma-2 (Bcl-2) inhibitor, a B-cell lymphoma-extra large (Bcl-xl) inhibitor, a casein kinase 2 (CK2) inhibitor, and/or a mediator complex subunit 1 (MEDl) for cancer. The combination therapy is expected to be synergistic in treating the cancer, compared to the monotherapy. Methods for identifying a subject having a cancer that is resistant to or at risk of developing resistance to bromodomain and extra terminal (BET) inhibitor therapy are also provided.
NºPublicación: WO2017026331A1 16/02/2017
UNIV OSAKA [JP]
Provided is an active ingredient of a pharmaceutical composition for myeloma therapy. This antibody has an epitope in a region comprising the 20th to 109th amino acid residues of human integrin β7.
NºPublicación: WO2017027829A1 16/02/2017
PORTOLA PHARM INC [US]
Compositions and methods for treating multiple myeloma (MM), acute myeloid lymphoma (AML) or a myeloproliferative disease (MPD) in a human patient in need thereof. The methods entail administering to the patient an effective amount of cerdulatinib.
NºPublicación: WO2017027403A1 16/02/2017
UNIV VIRGINIA PATENT FOUNDATION [US]
UNIV OF BIRMINGHAM THE [GB]
Provided are compositions that include one or more peptides, wherein each peptide is at least 8 amino acids long and has an amino acid sequence as set forth in any of SEQ ID NOs: 1-45. Also provided are in vitro populations of dendritic cells that include the disclosed compositions, in vitro populations of CD8+ T cells capable of being activated upon being brought into contact with the disclosed populations of dendritic cells, antibodies or antibody-like molecules that specifically bind to complexes of MHC class I molecules and the disclosed peptides, methods for treating and/or preventing cancer such as leukemia using the disclosed compositions and/or populations, methods for making cancer vaccines using the disclosed compositions, methods for screening target peptides for inclusion in an immunotherapy composition, methods for determining a prognosis of a leukemia patient, and kits that include at least one of the disclosed peptides.
NºPublicación: EP3129477A2 15/02/2017
MEMORIAL SLOAN-KETTERING CANCER CENTER [US]
The present invention relates to a Truncated isoform of Anaplastic Lymphoma Kinase ("TALK"). Expression of this isoform is associated with malignancy and with responsiveness to ALK inhibitors. Detection of the isoform may be used in diagnostic and therapeutic methods. Because it arises as a result of variant transcription rather than genetic rearrangement, its presence would be undetected by genomic testing.
NºPublicación: AU2015288060A1 09/02/2017
ACETYLON PHARMACEUTICALS INC
Provided herein are combinations comprising an HDAC inhibitor and azacitidine for the treatment of leukemia in a subject in need thereof. Provided herein are combinations comprising an HDAC inhibitor and azacitidine for the treatment of acute myelogenous leukemia in a subject in need thereof. Also provided herein are methods for treating leukemia in a subject in need thereof, comprising administering to the subject an effective amount of the above combination or an HDAC inhibitor, as well as methods for treating acute myelogenous leukemia in a subject in need thereof, comprising administering to the subject an effective amount of the above combination or an HDAC inhibitor.
NºPublicación: WO2017020065A1 09/02/2017
UNIV OF SOUTH AUSTRALIA [AU]
A novel class of inhibitors of protein kinases that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of CDK4, CDK6 and/or cyclin D, including certain cancers of lung, breast, brain, central nervous system, colorectal cancer and leukaemias. The inhibitors have the general structure I:
NºPublicación: WO2017024019A1 09/02/2017
CELGENE CORP [US]
A method of identifying a subject having chronic lymphocytic leukemia (CLL) who is likely to be responsive to a treatment compound, comprising obtaining a first sample and a second sample from the subject having CLL; administering 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione (Compound A) to the first sample and administering lenalidomide to the second sample; determining the level of a biomarker in the first sample and determining the level of the biomarker in the second sample; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the first sample is different from the level of the biomarker in the second sample.
NºPublicación: WO2017020128A1 09/02/2017
UNIVERSIT\u00C9 DE MONTR\u00C9AL [CA]
RSEM LTD PARTNERSHIP [CA]
Genes exhibiting specific mutational and/or transcriptional patterns in AMLs and various AML subtypes such as CBF-AMLs, t(8;21) AMLs, inv(16) AMLs; MLL-rearranged AMLs and other subtypes relative to other types of AMLs and/or normal CD34+ cells are disclosed. The use of these mutational and/or transcriptional patterns for the classification, diagnosis and treatment of AMLs is also disclosed.
NºPublicación: WO2017023859A1 09/02/2017
MEMORIAL SLOAN-KETTERING CANCER CENTER [US]
The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., multiple myeloma). It relates to anti-CD56 antibodies, chimeric antigen receptors (CARs) that specifically target human CD56, and immunoresponsive cells comprising such CARs. The presently disclosed CD56-specific CARs have enhanced immune-activating properties, including anti-tumor activity.
NºPublicación: WO2017021177A1 09/02/2017
UNIV BARCELONA [ES]
Combinations of a CDK 4/6 inhibitor and a glutaminase inhibitor are useful for the treatment of cancer, particularly: colon cancer, breast cancer, melanoma, glioblastoma, osteosarcoma, cervical cancer, lymphoma, squamous cell skin cancer, and glioma. A preferred CDK 4/6 inhibitor is 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin- 2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one hydrochloride. Preferred glutaminase inhibitors are bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide and 2-(pyridin-2- yl)-N-(5-(4-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl)butyl)-1,3,4- thiadiazol-2-yl)acetamide. The combinations present a synergistic effect in the treatment of mammals, including humans. The administration may be simultaneous, separated or sequential.
NºPublicación: WO2017021526A1 09/02/2017
AMGEN RES (MUNICH) GMBH [DE]
The present invention provides an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT for use in a method of treatment of a blood-borne cancer, in particular acute myeloid leukemia (AML). Moreover, the present invention provides a pharmaceutical composition comprising an inhibitor against CD1 12 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT and a CAR T cell. The present invention further provides a pharmaceutical composition comprising an inhibitor against CD1 12 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT and an antibody construct that is capable of engaging T cells.
NºPublicación: GB2541027A 08/02/2017
THE BINDING SITE GROUP LTD [GB]
A method of identifying whether a subject having a B-cell disease is suitable to be treated with intravenous immunoglobulin (IVIg) or in need of treatment with IVIg. The method comprising detecting the presence or absence of a monoclonal immunoglobulin associated with the B-cell disease wherein if the monoclonal immunoglobulin is IgA, IgD, IgM, light chain only, the B-cell disease is non-secretory multiple myeloma (MM) or if the concentration of total IgG is below a pre-determined amount in a sample from the subject, the patient is suitable to be treated with IVIg or if the amount of polyclonal IgG is below a predetermined amount, the patient is in need of treatment with IVIg. Also claimed is a method of monitoring IVIg levels in a subject comprising monitoring the IgGλ lambda to IgGκ kappa ratio or the concentration of IgGλ lambda or IgGκ kappa in a subject.
NºPublicación: EP3127551A1 08/02/2017
BOEHRINGER INGELHEIM VETMEDICA INC [US]
The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopalhy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (51) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
NºPublicación: US2017029904A1 02/02/2017
THE BRIGHAM AND WOMEN'S HOSPITAL INC [US]
TRUSTEES OF BOSTON UNIV [US]
Methods for diagnosing Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) based on a diagnostic score, as well as determining MYC activity levels and selecting treatments based on a MYC activity score.
NºPublicación: US2017029516A1 02/02/2017
CANTARGIA AB [SE]
The present disclosure provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1 RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting the binding of antibody ‘CAN04’ to human IL1 RAP. The disclosure further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of IL-1 associated diseases and conditions, including cancers such as acute myeloid leukemia and melanoma.
NºPublicación: US2017027932A1 02/02/2017
SIGNAL PHARM LLC [US]
Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
NºPublicación: US2017027936A1 02/02/2017
UCL BUSINESS PLC [GB]
The present invention relates to an Abelson murine leukaemia viral oncogene homolog 1 (ABL1) inhibitor for use in the treatment of ocular neovascularisation associated with a non-cancerous condition. The invention also relates to the use of an ABL1 inhibitor as a complementary therapy with VEGF or VEGF receptor inhibitor treatment and provides pharmaceutical compos itions and kits comprising one or both inhibitors.
NºPublicación: US2017027923A1 02/02/2017
CELGENE CORP [US]
Methods of treating, preventing or managing mantle cell lymphomas are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed.
NºPublicación: US2017029503A1 02/02/2017
MEDIMMUNE LTD [GB]
CAMBRIDGE ENTPR LTD [GB]
This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia.
NºPublicación: WO2017019559A1 02/02/2017
UNIV OF UTAH RES FOUND [US]
Disclosed are methods are of treating acute myeloid leukemia (AML) comprising administering an effective amount of a first AML therapeutic and an effective amount of a second AML therapeutic. Also disclosed are methods of treating AML comprising administering an effective amount of a first AML therapeutic conjugated to N-(2- hydroxypropyl)methacrylamide (HPMA) copolymer. Also disclosed are methods of treating AML comprising administering an effective amount of a first AML therapeutic conjugated to HPMA copolymer, wherein the first AML therapeutic conjugated to HPMA copolymer comprises a HPMA copolymer backbone comprising at least two HPMA copolymer segments connected by a degradable peptide sequence.
NºPublicación: WO2017018499A1 02/02/2017
DAIICHI SANKYO CO LTD [JP]
THE UNIV OF TOKYO [JP]
The present invention provides a therapeutic and/or prophylactic agent for adult T cell leukemia/lymphoma comprising a compound having a specific chemical structure or a pharmaceutically acceptable salt thereof. The active ingredient of the therapeutic and/or prophylactic agent for adult T cell leukemia/lymphoma is 7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5- carboxamide or a pharmaceutically acceptable salt thereof, or 7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide or a pharmaceutically acceptable salt thereof.
NºPublicación: US2017030910A1 02/02/2017
UNIV ZUERICH [CH]
The invention provides for a method for the detection of FeLV infection in a patient, wherein a sample obtained from the patient is contacted in-vitro with a recombinant transmembrane p15E protein in a p15 (E) antibody binding step.
Nº publicación: US2017029899A1 02/02/2017
SINGAPORE HEALTH SERV PTE LTD [SG]
Natural-KilleifT-Cell Lymphoma (NKTCL) susceptibility prediction, diagnosis and therapy. The invention relates to a method for predicting Natural Killer T-cell Lymphoma (NKTCL) susceptibility and/or diagnosing NKTCL in a subject comprising testing for JAK mutations. The invention also relates to a method of screening for candidate agents capable of treating NKTCL using a cell line comprising at least one JAK mutation. The invention includes an NKTCL animal model comprising at least one JAK mutation. The invention also includes JAK inhibitors for treating NKTCL.